Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 9/20 | 0.60 |
| ▸ | PARP2 | Q9UGN5 | 3/20 | 0.60 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.51 |
| ▸ | TNKS | O95271 | 1/20 | 0.50 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.50 |
| ▸ | PARP14 | Q460N5 | 7/20 | 0.49 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6795593 | 0.83 | PARP1 (0.64) | PARP1PARP2HCAR2TNKS2PDE10A | |
| SCHEMBL6795780 | 0.81 | PARP1 (0.61) | PARP1PARP2HCAR2TNKS2PDE10A | |
| SCHEMBL6795464 | 0.79 | PARP1 (0.63) | PARP1PARP2HCAR2TNKS2PDE10A | |
| SCHEMBL19953291 | 0.79 | PARP1 (0.66) | PARP1PARP2TNKSTNKS2PARP14 | |
| SCHEMBL6796643 | 0.78 | PARP1 (0.53) | PARP1PARP2PARP14PARP11PDE10A | |
| SCHEMBL20355545 | 0.77 | PARP1 (0.71) | PARP1PARP2TNKSTNKS2PARP14 | |
| SCHEMBL6644094 | 0.77 | PARP1 (0.63) | PARP1PARP2TNKSTNKS2PARP14 | |
| SCHEMBL31483741 | 0.76 | PARP1 (0.69) | PARP1PARP2TNKSTNKS2PARP14 | |
| SCHEMBL21072527 | 0.76 | PARP1 (0.69) | PARP1PARP2TNKSTNKS2PARP14 | |
| SCHEMBL6646176 | 0.76 | PARP1 (0.62) | PARP1PARP2TNKSTNKS2PARP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077667-A1 | Quinazolinone derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077667-A1 | Quinazolinone derivatives | PARP1, PARP9, PARP2 | PARP1 1/4885PARP2 3/4885HCAR2 3453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.